Optiver Holding
SYRE icon

Optiver Holding’s Spyre Therapeutics SYRE Stock Holding History

Optiver Holding’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.5K Buy
400
+112
+39% +$8.17K ﹤0.01% 1271
2026
Q1 		$14.5K Buy
288
+48
+20% +$1.81K ﹤0.01% 1151
2025
Q4 		$7.86K Sell
240
-260
-52% -$6.79K ﹤0.01% 1200
2025
Q3 		$8.38K Buy
+500
New +$8.15K ﹤0.01% 1406

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Optiver Holding's SYRE Position: Q2 2026 in Review

Optiver Holding increased its Spyre Therapeutics (SYRE) stake by 39% in Q2 2026, buying an estimated $8.17K and bringing the position to 400 shares worth $35.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1271.

Optiver Holding first reported a position in SYRE in Q3 2025 and has held it in 4 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Optiver Holding held 400 shares of Spyre Therapeutics worth $35.5K as of Q2 2026.
  • Optiver Holding bought 112 Spyre Therapeutics shares in Q2 2026, an estimated $8.17K.
  • Spyre Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1271 holding.
  • Optiver Holding first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.